Perspective Therapeutics (CATX) Free Cash Flow (2010 - 2026)

Perspective Therapeutics has disclosed Free Cash Flow across 17 years of filings, most recently posting -$31.5 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$31.5 million, down 45.75% year-over-year; the trailing twelve-month figure through Mar 2026 was -$92.5 million (up 14.47% YoY), and the FY2025 annual result was -$82.6 million, down 13.63% from the prior year.
• Free Cash Flow came in at -$31.5 million for Q1 2026 at Perspective Therapeutics, down from -$24.7 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $13.8 million in Q1 2024 to a low of -$81.0 million in Q4 2024.
• The 5-year median for Free Cash Flow is -$9.9 million (2023), against an average of -$14.0 million.
• Peak annual rise in Free Cash Flow reached 239.54% in 2024, while the deepest fall reached 790.36% in 2024.
• Perspective Therapeutics' Free Cash Flow stood at -$6.2 million in 2022, then slumped by 45.86% to -$9.1 million in 2023, then plunged by 790.36% to -$81.0 million in 2024, then surged by 69.49% to -$24.7 million in 2025, then decreased by 27.36% to -$31.5 million in 2026.
• The last three Free Cash Flow figures came in at -$31.5 million (Q1 2026), -$24.7 million (Q4 2025), and -$16.3 million (Q3 2025), per Business Quant data.